FRONTEO, Inc. 1Q Earnings Preview

Focus on AI drug discovery co-creation project pipeline build-up, progress in business portfolio restructuring, and profitability during the upfront investment phase

PublishedAugust 12, 2026 at 15:30 GMT+9

Summary

FRONTEO returned to a growth trajectory in FY2026/3 with revenue up +25.3% YoY, but has guided for operating income of JPY 300M (▲59.4%) in FY2027/3, reflecting a plan that incorporates upfront investments. In 1Q, the pace of new co-creation project wins in the AI drug discovery business will be closely watched. While the impact of the US legal tech business withdrawal has largely run its course, goodwill amortization and capital commitments to DDAIF Innovation Bridge weigh on the cost structure—making this a quarter where the balance between the "magnitude" of upfront investment and the "velocity" of monetization will be tested. Expansion of the drug discovery ecosystem, underpinned by the proprietary equation-driven AI "KIBIT" technology, will be a key determinant of the feasibility of the mid-term management plan (Stage 4, targeting FY2029/3).

Key Points for Next Quarter

Key Points & Focus	Implications
AI Drug Discovery Revenue GrowthNew co-creation project contract count and 1Q revenue	Confirming sustainability of prior-year AI drug discovery segment revenue of JPY 751M (+511.7%). Given the H2-weighted plan, how 1Q revenue lands relative to the full-year target is critical
Life Science AI Business BreakevenSegment operating income/loss trajectory	Prior year posted an operating loss of JPY ▲16M. The company targets breakeven this fiscal year; watch for signs of P&L improvement in 1Q
Legal Tech AI Segment BottomingCompletion of US business withdrawal impact and domestic forensics order flow	Prior-year segment revenue was JPY 2,136M (▲38.8%). After the roll-off of US withdrawal-related costs, the pace of domestic business recovery will determine revenue base stability
Business Portfolio RestructuringKorean subsidiary divestiture and segment reclassification impact	Announced Korean subsidiary divestiture in July. Combined with the transfer of the BI & Professional Services division to Risk Management, scrutinize the P&L impact of changes in segment composition
SDS-881 Regulatory ReviewProgress on regulatory approval of dementia diagnostic AI medical device	Targeting approval within FY2026. Upon approval, milestone fee receipt and the creation of a new market would enhance the credibility of the medium-term growth scenario
Mid-Term Management Plan KPIsRevenue and margin progress toward Stage 4 (FY2029/3 target)	Full-year guidance calls for revenue of JPY 7,600M (▲0.6%) and operating income of JPY 300M (▲59.4%). Assess the investment payback timeline and probability of mid-term plan achievement
Financial SoundnessInterest-bearing debt balance and cash flow-to-debt ratio	Interest-bearing debt increased at prior FY-end (CF-to-debt ratio of 12.5x), with cash on hand of JPY 1,724M. Sustainability of the balance between investment burden and financial health is the key focus

Key Issues from Previous Results (FY2026/3 Full-Year)

FY2026/3 delivered revenue of JPY 7,643M (+25.3%) and operating income of JPY 739M (+40.1%), achieving top- and bottom-line growth. Expansion of the DX business through the Arnetz consolidation and rapid growth in the AI drug discovery segment drove performance, while the US legal tech business withdrawal and rising costs associated with increased borrowings partially offset profit growth. In preparation for mid-term management plan Stage 4, the centralization of the Life Science AI business and business portfolio restructuring are accelerating, positioning this period as a "structural earnings transformation phase."

1. AI Drug Discovery Revenue Expansion and Deepening of Co-Creation Ecosystem

Prior Year
: AI drug discovery segment revenue JPY 751M (+511.7%), 10+ co-creation partners, basic joint research agreement signed with UBE
This Year — Key Checkpoints
: Pace of new co-creation project wins, occurrence of success-based fees from the comprehensive co-creation model, progress on additional DDAIF Innovation Bridge deals (Scohia Pharma, etc.)
Key Metrics
: 1Q revenue level for the AI drug discovery segment, contract count and order backlog trajectory for co-creation projects

The AI drug discovery segment surged to JPY 751M in revenue (+511.7% YoY) in the prior fiscal year, lifting total Life Science AI business revenue to JPY 1,033M (+191.4%). Pharmaceutical co-creation partners now exceed 10 companies, including major names such as Daiichi Sankyo, Chugai Pharmaceutical, and Santen Pharmaceutical. New business models, including the comprehensive co-creation model (Maruishi Pharmaceutical) and DDAIF Innovation Bridge (NB Health Laboratory, etc.), have also begun contributing to revenue.

2. Dementia Diagnostic AI Medical Device (SDS-881) Regulatory Review and Non-Medical Device Deployment

Prior Year
: AI medical device segment revenue JPY 281M (+21.5%), Talk Lab KIBIT began generating revenue, participation in AMED dementia R&D project confirmed
This Year — Key Checkpoints
: SDS-881 clinical trial progress and regulatory review status, new alliance partner acquisition for Talk Lab KIBIT, progress on indication expansion into schizophrenia, ADHD, etc.
Key Metrics
: Approval filing/acquisition timeline, quarterly revenue trajectory for the AI medical device segment

SDS-881, co-developed with Shionogi, is in ongoing clinical trials with a target of obtaining manufacturing and marketing approval within FY2026. The non-medical device "Talk Lab KIBIT" has been deployed at Nippon Life and Asahi Life, establishing a foundation for cross-industry alliances.

3. Risk Management Business Structural Transformation and Sustained Economic Security Growth

Prior Year
: Risk Management business operating income JPY 606M (▲8.1%), US subsidiary withdrawal costs of JPY 119M booked, Economic Security segment +28.2% growth
This Year — Key Checkpoints
: Recovery in domestic forensics orders in the Legal Tech AI segment, new deployment count for KIBIT Seizu Workflow/Analysis, revenue trends in the BI & Professional Services division following segment transfer
Key Metrics
: Risk Management business 1Q revenue and OPM (vs. prior-year segment margin of 15.1%)

Total Risk Management business revenue declined to JPY 4,019M (▲25.2%) in the prior year, primarily driven by the revenue decline in the Legal Tech AI segment (▲38.8%) following the US subsidiary withdrawal. The Economic Security segment, however, expanded steadily to JPY 545M (+28.2%), with enhanced functionality for KIBIT Seizu Analysis and the productization of KIBIT Seizu Workflow progressing.

4. Arnetz Integration Benefits and DX Business Profitability

Prior Year
: DX business operating income JPY 149M (+49.6%), Arnetz standalone revenue JPY 2,325M (11 months), goodwill amortization approximately JPY 73M annually
This Year — Key Checkpoints
: Revenue level from full-year Arnetz contribution, Mendix × KIBIT cross-sell results, profitability of the DX business (Arnetz standalone) following the Professional Services division transfer
Key Metrics
: DX business 1Q OPM, underlying earnings power after goodwill and customer-related asset amortization

The consolidation of Arnetz (April 30, 2025; acquisition cost of JPY 1,554M) drove DX business revenue to JPY 2,590M (+598.9%). Goodwill of JPY 1,107M (amortized on a straight-line basis over 15 years, approximately JPY 73M annually) and customer-related intangible assets of JPY 213M have been recognized, creating a structure where amortization charges weigh on profits.

5. Financial Health and Investment Burden Balance

Prior Year
: Cash on hand JPY 1,724M (down JPY ▲870M from JPY 2,594M in the prior year), equity ratio 39.7%, CF-to-debt ratio 12.5x
This Year — Key Checkpoints
: Cash inflow from Korean subsidiary divestiture, short-term borrowing repayment/refinancing status, scale of additional capital commitments related to DDAIF Innovation Bridge
Key Metrics
: Operating cash flow, equity ratio trajectory, whether the interest coverage ratio improves

Interest-bearing debt increased at FY-end to JPY 2,600M in short-term borrowings, JPY 441M in current portion of long-term debt, and JPY 957M in long-term borrowings, with the equity ratio declining to 39.7% (vs. 45.9% in the prior year). Investing cash flow was JPY ▲2,549M (Arnetz acquisition JPY ▲1,063M, investment securities acquisition JPY ▲680M, intangible asset acquisition JPY ▲625M), reflecting continued aggressive investment. Against operating cash flow of JPY 321M, the interest coverage ratio has declined to 6.5x.

Timely Disclosure & Industry Trends

2026/07/22
Divestiture of Korean subsidiary FRONTEO Korea — Part of business portfolio optimization. A strategic decision to accelerate management resource concentration on the Life Science AI business, with a positive impact on the Risk Management business cost structure. FRONTEO divests Korean subsidiary as part of business portfolio optimization
2026/07/16
Launch of second co-creation project with Santen Pharmaceutical — A follow-on engagement with a major ophthalmology player, demonstrating DDAIF's credibility and lateral expansion capability. May contribute to 1Q AI drug discovery revenue. FRONTEO and Santen Pharmaceutical launch second co-creation project
2026/07/14
AI predictive model for toxicology study reports built with Daiichi Sankyo — A result demonstrating expanded DDAIF application into drug safety evaluation. Deepening relationships with major pharma broadens the potential for evolving into comprehensive co-creation models. FRONTEO and Daiichi Sankyo build predictive model for automated extraction of toxicological interpretations from toxicology study reports
2026/07/10
Launch of new economic security application "KIBIT Seizu Workflow" — Productized from a Cabinet Office project. Expected to drive adoption across universities and research institutions by streamlining research security operations. FRONTEO launches new application "KIBIT Seizu Workflow" to support research security operations
2026/05/28
DDAIF utilization agreement and equity investment with Scohia Pharma — A new DDAIF Innovation Bridge deal. Accompanied by a third-party allotment share subscription, demonstrating expansion of the collaborative drug discovery ecosystem. FRONTEO and Scohia Pharma sign agreement on novel indication exploration utilizing AI drug discovery support service "DDAIF"

Previous Quarter Results (FY2026/3 Full-Year Actuals)

FRONTEO operates three segments built on its equation-driven AI "KIBIT" platform: Life Science AI (AI drug discovery, AI medical devices), Risk Management (compliance support, legal tech, economic security), and DX. Under mid-term management plan Stage 4 (FY2029/3 target), the Life Science AI business is positioned as the core business, pursuing discontinuous growth through the construction of a drug discovery ecosystem. The prior fiscal year saw revenue growth recover to +25.3%, driven by the Arnetz consolidation and co-creation project expansion, with results exceeding the full-year plan (revenue JPY 7,000M). On the other hand, the FY2027/3 guidance projects operating income declining ▲59.4%, incorporating upfront investments—signaling a deepening investment phase.

Item	Amount	YoY	vs. Guidance	Remarks
Revenue	JPY 7,643M	+25.3%	-	Arnetz consolidation +JPY 2,219M and AI drug discovery +JPY 628M were key drivers
Operating Income	JPY 739M	+40.1%	-	OPM 9.7% (vs. 8.6% prior year), includes US withdrawal costs of JPY 119M
Recurring Profit	JPY 675M	+24.1%	-	Interest expense +JPY 28M and syndicated loan fees +JPY 34M pushed up non-operating expenses
Net Income	JPY 544M	▲2.0%	-	Reversal of prior-year tax effect benefits. Extraordinary income includes reversal of stock acquisition rights of JPY 62M
EPS	JPY 13.86	▲1.7%	-	Treasury stock acquisition (JPY 199M) resulted in a slight decrease in weighted average share count

FY2027/3 Full-Year Company Guidance: Revenue JPY 7,600M (▲0.6%), Operating Income JPY 300M (▲59.4%), Recurring Profit JPY 250M (▲63.0%), Net Income JPY 150M (▲72.4%), EPS JPY 3.82

FRONTEO, Inc.